Shares of the biotech fell around 15% on news the FDA is not only taking longer to review the drug, but will assemble an ...

Biohaven (BHVN) stock slides as the FDA delays review of its lead drug troriluzole for a neurological condition called ...

Pfizer's stock has taken a tumble, but the story isn’t over—it's just pivoting to the next act. Once flying high on pandemic ...

A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

AAN conference featured the latest research and developments in neurological disorders like Alzheimer's disease, epilepsy and ...

Fremanezumab reduced migraine attacks and depression symptoms in migraine patients with major depressive disorder.

Officials with Arvinas, a New Haven-based biotechnology firm, announced Thursday that the company is laying off 131 workers at the end of June, including 92 in Connecticut. The company announced its ...

Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US ...

Since 2020, Pfizer has made significant investments in acquisitions, including Seagen for $43 billion, Biohaven for $13 billion, Arena for $6 billion, Global Blood Therapeutics (GBT) for $5.4 billion ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and ...